During the past decade, Sutter Hematology and Oncology conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Sutter Hematology and Oncology" are "Lymphoma, Non-Hodgkin" (2 trials), "Lymphoma, B-Cell" (1 trials), "Lymphoma, Large B-Cell, Diffuse" (1 trials), "Lymphoma, Nonhodgkin" (1 trials) and "Neoplasms" (1 trials). Many other conditions were trialed in "Sutter Hematology and Oncology" in a lesser frequency.

Most popular intervention types in "Sutter Hematology and Oncology" are "Biological" (1 trials), "Drug" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Gene-modified (GM) T cell therapy" (1 trials), "Lenalidomide" (1 trials), "Rituximab" (1 trials) and "lisocabtagene maraleucel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sutter Hematology and Oncology" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Sutter Hematology and Oncology". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Sutter Hematology and Oncology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Sutter Hematology and Oncology, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".